Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    Home»BioTech»Olympus Launches Venture Capital Fund to Strengthen Medtech Leadership
    BioTech

    Olympus Launches Venture Capital Fund to Strengthen Medtech Leadership

    Marie JonesBy Marie JonesNovember 12, 2021No Comments4 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email
    • Initial fund targets medical devices, digital solutions, and diagnostics

    Olympus Corporation (Tokyo: 7733), a global leader in medical technology, has announced the establishment of Olympus Innovation Ventures to invest in pioneering startups with innovative technologies that improve clinical outcomes, reduce healthcare costs and enhance the quality of life for patients.

    Olympus Innovation Ventures, a fully-owned subsidiary of Olympus Corporation of the Americas, is a venture capital fund focused on startups poised to improve patient outcomes, radically advance the detection and treatment of disease, and transform the surgery suite. The new fund expands upon Olympus’ strategy to strengthen endoscopy and pioneer next-generation tools and procedures for minimally invasive surgery.

    Olympus’ venture fund is stage-agnostic, prioritizing early- and growth-stage companies globally with solutions in therapeutic areas including gastroenterology, respiratory, and urology. Olympus has allocated $50 million for initial commitments and follow-on investments in portfolio companies. In addition to capital, Olympus will help its portfolio companies succeed by contributing its clinical and technical expertise, access to healthcare professionals and hospitals, and ability to launch and scale innovative solutions in the global market.

    Olympus has been a leader in optical and medical innovation for over 100 years, introducing a mass-produced microscope to Japan in 1919 and the world’s first gastrocamera for practical use in 1950. Olympus’ tools have aided the minimally invasive surgery revolution and have evolved to detect and treat disease. Yasuo Takeuchi, CEO of Olympus Corporation, says “Our investment underscores our commitment to make people’s lives safer, healthier, and more fulfilling. Our goal is for this fund to continue our history of innovation and support our long-term growth and transformation.”

    Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the Olympus Innovation Ventures fund. Touchdown will work closely with senior executives of Olympus in all aspects of operating the fund.

    “We are excited about what Olympus can bring to entrepreneurs through the company’s technical strengths, industry relationships, vast distribution, and deep subject matter expertise,” noted Scott Lenet, co-founder and President of Touchdown Ventures. “The entire Olympus Innovation Ventures team is working to be the partner of choice for innovators and create a competitive advantage for their startups.”

    Nacho Abia, Chief Operating Officer of Olympus Corporation, said “This effort is another way Olympus is demonstrating its commitment to excellence and creating tangible value for providers and patients. We believe we will play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor and treat conditions and diseases.”

    For more information, please visit http://olympusamerica.com/venture-capital. Olympus Innovation Ventures can be contacted at ventures@olympus.com.

    For the contact:
    Olympus Corporation of the Americas
    Christos Monovoukas
    Vice President, Global Business Development
    Christos.Monovoukas@Olympus.com

    Touchdown Ventures
    Deborah Zajac
    Director, Investments
    deborah@touchdownvc.com

    About Olympus
    Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus’ Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.

    About Touchdown Ventures
    Touchdown Ventures partners with corporations to manage their venture capital programs. Touchdown works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm is a Registered Investment Adviser and maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on Touchdown can be found at www.touchdownvc.com

    Olympus Contact (Tokyo)
    Yuka Horimoto
    +81-90-2490-1071
    yuka.horimoto@olympus.com

    Olympus Contact (USA)
    Susan Scerbo
    +1-610-909-9153
    sue.scerbo@olympus.com

    Touchdown Ventures Contact
    Deborah Zajac
    Director, Investments
    +1-917-558-4403
    deborah@touchdownvc.com

    Olympus
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleTam Jai International’s Revenue Increases by 43% to HK$1,181 Million and Adjusted Profit Surges by 108% to HK$147 Million in 1H2022
    Next Article American Blockchain PAC Launches to Advance Blockchain and Cryptocurrency Innovation in America

    Related Posts

    CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth

    October 27, 2026

    Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

    October 27, 2026

    Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization

    October 27, 2026
    Add A Comment

    Comments are closed.

    Latest News

    • Chervon Launches Advanced Momentum Program (AMP) to Hire & Develop the Next Generation of Leaders
    • Autumn Lighting Fair, Outdoor and Tech Light Expo, Eco Expo Asia draw some 62,000 buyers
    • OMRON Healthcare Begins Full-Scale Production at First Factory in India
    • CIMC Group Announces Results for the First Three Quarters of 2026
    • TANAKA MIRAI Lab., JAF MEDIA WORKS, and Della Begin Joint Research to Visualize Drivers’ Conditions through Analysis of Sweat Components
    • U.S. Polo Assn. Executes Early on Europe’s Digital Product Passport Mandate
    • COSCO SHIPPING Ports Announces 2026 Third Quarter Results
    • JCB Partners with Hanoi Metro to Introduce JCB Contactless Payment in Hanoi
    • Smokers in New Zealand are Still Waiting for a Promised Reform
    • GA-ASI and Saab Perform Advanced AEW Flight Testing on Uncrewed MQ-9B
    © 2026 BusinessNewsAsia.com

    Type above and press Enter to search. Press Esc to cancel.